Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
April 23, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...
TAOP Raises $2 Million from Recent Financing
March 30, 2020 08:00 ET
|
Taoping Inc.
SHENZHEN, China, March 30, 2020 (GLOBE NEWSWIRE) -- Taoping Inc. (NASDAQ: TAOP, the “Company”), a leading provider of internet-based smart display screens, and a new-media ecosystem that enables...
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 12, 2020 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year...
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
March 05, 2020 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo
April 02, 2019 12:56 ET
|
NANOBIOTIX
Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo ...
Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
April 02, 2019 12:56 ET
|
NANOBIOTIX
Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in combination with a PD-1...
Allant Group Boosts Big Data Analytics With 16X Performance Improvement Using Kaminario K2
July 17, 2013 11:00 ET
|
Kaminario
NEWTON, MA--(Marketwired - Jul 17, 2013) - Kaminario, the leading scale-out all-flash array provider, today announced that Allant Group, a leading marketing and audience management platform, has...
Conatus Capital Management Increases Storage Performance by 600 Percent Using Kaminario K2 in Its Virtualized Environment
July 11, 2013 11:00 ET
|
Kaminario
NEWTON, MA--(Marketwired - Jul 11, 2013) - Kaminario, the leading scale-out all-flash array provider, today announced that Conatus Capital Management LP ("Conatus"), a Connecticut-based investment...